PPG is pleased to announce that P. Brian Giles, J.D., Ph.D., has joined the firm, bringing deep scientific knowledge and extensive experience in biotechnology patent law to our growing team.

Dr. Giles focuses his practice on U.S. and international biotechnology patent prosecution, portfolio management, and intellectual property due diligence. With a Ph.D. in Molecular and Cellular Biology and more than a decade of laboratory research experience, he provides strategic, science-driven counsel to clients ranging from universities to early- and growth-stage biotech companies.

“We are thrilled to welcome Brian to PPG,” said Eli Monheit, Chief Operating Officer. “His technical depth and client-centered approach align perfectly with our mission to provide exceptional IP strategy and protection to innovators in the life sciences.”

Dr. Giles has supported clients across a broad range of technologies, including immunotherapies, viral vectors, diagnostics, recombinant proteins, stem cells, and medical devices. His experience includes drafting and prosecuting patent applications, conducting freedom-to-operate and patentability analyses, and advising on IP strategy during licensing and M&A transactions.

With the addition of Dr. Giles, PPG continues to expand its capabilities and deepen its commitment to serving the scientific and academic communities with thoughtful, forward-looking intellectual property solutions.